English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
Prenetics旗下的行动基因的ACTOnco® IVD产品获得FDA许可 成为首家就适用于所有实体肿瘤的癌症基因检测取得许可的亚洲公司
Jan 11, 2023 11:21 HKT
Prenetics旗下的行動基因的ACTOnco® IVD產品獲得FDA許可 成為首家就適用於所有實體腫瘤的癌症基因檢測取得許可的亞洲公司
Jan 11, 2023 11:20 HKT
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
Jan 11, 2023 11:19 HKT
君聖泰HTD1801治療非酒精性脂肪性肝炎(NASH)的臨床IIb 期研究(CENTRICITY研究)完成首例患者給藥
Jan 11, 2023 08:01 HKT
君圣泰HTD1801治疗非酒精性脂肪性肝炎(NASH)的临床IIb 期研究(CENTRICITY研究)完成首例患者给药
Jan 11, 2023 08:00 HKT
China Biotech Services subsidiary AMDL nominated as Top Clinical Laboratory Services Company in APAC 2022 and receives CAP Accreditation Certificate
Jan 10, 2023 16:33 HKT
Malaysian Genomics Explores R&D Collaboration with SIRIM
Jan 09, 2023 14:00 HKT
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations
Jan 05, 2023 18:00 HKT
逆勢融資1億+美元,這家創新藥Biotech有何獨特之處?
Jan 05, 2023 11:52 HKT
逆势融资1亿+美元,这家创新药Biotech有何独特之处?
Jan 05, 2023 11:51 HKT
君聖泰完成1.07 億美元C/C+輪融資,加速推進在研管線的全球開發、商業化和商務拓展
Jan 05, 2023 08:01 HKT
君圣泰完成1.07 亿美元C/C+轮融资,加速推进在研管线的全球开发、商业化和商务拓展
Jan 05, 2023 08:00 HKT
四环医药(0460.HK):惠升生物成功完成A +轮融资,加速糖尿病及并发症领域布局
Jan 04, 2023 09:57 HKT
四環醫藥(0460.HK):惠升生物成功完成A +輪融資,加速糖尿病及併發症領域佈局
Jan 04, 2023 09:56 HKT
Sihuan Pharmaceutical (0460.HK): Huisheng Biopharmaceutical Successfully Completes A+ Round of Financing, Accelerating the Layout of Diabetes and Complications
Jan 04, 2023 09:55 HKT
博安生物公布H股全球发售配发结果
Dec 29, 2022 09:50 HKT
博安生物公佈H股全球發售配發結果
Dec 29, 2022 09:49 HKT
Boan Biotech Announces Global Offering Allotment Results of H Shares
Dec 29, 2022 09:48 HKT
全球主要医疗器械制造商业聚医疗集团之股份于香港联交所主板挂牌上市
Dec 23, 2022 15:12 HKT
全球主要醫療器械製造商業聚醫療集團之股份於香港聯交所主板掛牌上市
Dec 23, 2022 15:11 HKT
<< Previous  Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: